



Review

Nuclear Import of Arachidonate 5-Lipoxygenase

THOMAS G. BROCK* and ANNETTE M. HEALY

Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA

Abstract. Leukotrienes are lipid messenger molecules that are secreted by leukocytes to orchestrate a rapid and prolonged immune response. The enzyme 5-lipoxygenase catalyzes the rate-limiting first two steps in the synthesis of leukotrienes from arachidonic acid. Although it has long been known that 5-lipoxygenase moves from the cytoplasm to a membrane **following** activation, it has only recently been recognized that the enzyme may shuttle into and out of the nucleus **before** activation. The regulation of this movement of soluble 5-lipoxygenase between the cytoplasm and the nucleoplasm, as well as its impact on 5-lipoxygenase action, leukotriene synthesis and cell function, is only now being elucidated. This review details the state of our understanding of the nuclear import of 5-lipoxygenase and its potential importance in immunity.

Key words: leukotrienes; 5-lipoxygenase; nuclear import.

Introduction

Leukotrienes (LTs) are intercellular messengers that play initiating roles in host defense. LTB₄ regulates inflammation, acting to recruit and activate leukocytes as well as modulate the production of pro-inflammatory cytokines. The cysteinyl LTs, LTC₄ and LTD₄, normally regulate vasoconstriction, mucus secretion and edema. However, the over-production of LTs contributes to disease, including asthma¹⁵ and allergic hyperresponsiveness³². Similarly, the under-production of LTs, as occurs in neonates^{8, 35} or with viral infection¹⁰, results in reduced phagocytosis and killing of bacteria and, in this way, increases susceptibility to persistent bacterial infection², as may be associated with pneumonia, sepsis and meningitis.

The enzyme 5-lipoxygenase (5-LO) catalyzes the rate-limiting first two steps in the synthesis of LTs from the fatty acid substrate, arachidonic acid (AA) (Fig. 1).




Fig. 1. Key enzymes in the synthesis of LTs from AA. 5-LO and its activating protein, FLAP, mediate the rate-limiting first steps. LTA₄ hydrolase and LTC₄ synthase convert LTA₄ to the active products LTB₄ and LTC₄, respectively

Abbreviations used: AA – arachidonic acid, FLAP – 5-lipoxygenase activating protein, 5-HPETE – 5-hydroperoxyeicosatetraenoic acid, 5-HETE – 5-hydroxyeicosatetraenoic acid, 5-LO – 5-lipoxygenase, LT – leukotriene, NIS – nuclear import sequence.

* Correspondence to: Thomas G. Brock, Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109-0642, USA, tel.: +1 734 763 90 77, fax: +1 734 764 45 56, e-mail: brocko@umich.edu

5-LO first inserts molecular oxygen into AA to form 5-hydroperoxyeicosatetraenoic acid (5-HPETE) and, subsequently, directs a dehydration step to produce LTA_4 ^{28, 34}. The activity of 5-LO is greatly enhanced by the 5-LO-activating protein (FLAP)^{1, 14}, although FLAP is not necessary for 5-LO action. The intermediate 5-HPETE is often made in significant amounts; it is rapidly modified to 5-hydroxyeicosatetraenoic acid (5-HETE). The end-product of 5-LO action, LTA_4 , can be either hydrolyzed by the enzyme LTA_4 hydrolase to give LTB_4 , or conjugated with glutathione by the enzyme LTC_4 synthase to produce LTC_4 . LTC_4 may be further metabolized to LTD_4 and LTE_4 .

Movement of 5-LO Following Cell Stimulation

The 5-LO enzyme can move in at least two distinct patterns within the cell. One pattern involves its movement from the soluble phase to a bound phase, as it becomes associated with intracellular membranes (Fig. 2). This movement, which has long been recognized³³, is taken as a hallmark of 5-LO activation and occurs following cell stimulation. The movement is commonly alluded to as „translocation” and is triggered by the transient increase in cytoplasmic calcium concentration that follows cell stimulation. Membrane association is rapid, as it is evident within seconds after cell stimulation⁶, when assayed by immunofluorescent techniques.




Fig. 2. The movement of cytoplasmic 5-LO to subcellular membranes. In unstimulated peripheral blood neutrophils, 5-LO is dispersed in the cytoplasm, as shown by immunofluorescent microscopy (A) and diagrammatically (C). After cell stimulation, 5-LO accumulates predominantly on the outer membrane of the nuclear envelope surrounding the multi-lobed nucleus (B, D)

Functionally, membrane association serves to place 5-LO close to its substrate, AA, as well as its activating protein FLAP. This facilitates the production of high levels of secretable LTs. Recent studies have demonstrated that 5-LO accumulates most abundantly at the nuclear envelope and endoplasmic reticulum⁶. Calcium-dependent membrane association of 5-LO appears to be reversible following transient stimulation^{6, 19, 25}. Persistent membrane association results from chronic cell stimulation⁶ and may be indicative of persistent LT synthesis linked to disease³⁶. Since the 5-LO enzyme is readily inactivated by its own action^{21, 26}, the persistent membrane association resulting from extensive cell stimulation can also be a marker for inactivated 5-LO⁶.

Movement of 5-LO Before Cell Stimulation

A second type of movement of 5-LO, which has only recently been recognized, is its import, still as a soluble protein, into the nucleus. Nuclear import of proteins is also commonly referred to as “translocation”; this overlap in terminology has undoubtedly caused confusion regarding 5-LO movement. Nuclear import is distinct from membrane association, both mechanistically and functionally. In general terms, the enzyme remains soluble during nuclear import, moving from the cytoplasm to the nucleoplasm. When visualized within the nucleoplasm by immunofluorescent techniques, soluble 5-LO distributes in a distinctive “flecked” pattern (Fig. 3). Following cell stimulation, the enzyme may be induced to move to the nuclear envelope by an increase in the calcium concentration within the nucleoplasm. Visually, 5-LO appears to be distributed across a membrane, and folds in the membrane are often apparent.




Fig. 3. The movement of intranuclear 5-LO to the nuclear envelope. In the mast cell-like rat basophilic leukemia cells, 5-LO is most abundant in the nucleoplasm before cell stimulation, as shown by immunofluorescent microscopy (A). After cell stimulation, 5-LO accumulates predominantly on the inner membrane of the nuclear envelope (B). An increase in the volume of the nucleus is a normal event immediately following cell stimulation

The mechanism of nuclear import has been the subject of several recent reviews^{16, 17, 27}. Import of proteins larger than 50 kDa, such as 5-LO, occurs through a signal-mediated pathway. Typically, the protein to be imported must contain a nuclear import sequence (NIS) that mediates association with a cytoplasmic receptor protein. The best-characterized NIS consists of a cluster of basic amino acids (arginine or lysine) that are recognized by the cytoplasmic receptor, importin α . Binding to importin α allows association with importin β , docking at the nuclear pore, and entrance into the nucleus.

The mechanism by which 5-LO is imported into the nucleus has only recently received attention. Preliminary studies suggested that, although 5-LO contains three basic regions that resemble NISs, none of these were necessary for nuclear import⁹. However, a more thorough analysis of these sequences identified a bipartite NIS in the carboxyl terminus that is essential for nuclear import¹⁸. Mutational analysis revealed that the replacement of specific basic amino acids with uncharged residues impaired or eliminated nuclear import. Although this NIS, by itself, was able to direct the nuclear import of a heterologous protein, its import was less efficient than that of the 5-LO protein. Thus, the context in which the 5-LO NIS functions may determine its effectiveness. The cytoplasmic receptor (e.g., importin α) that mediates 5-LO import has not yet been identified.

The Regulation of Nuclear Import of 5-LO

Recent studies have demonstrated that the nuclear import of 5-LO can be activated by adherence^{4, 5} and cytokine stimulation¹², indicating that this process is regulated. The signaling pathways that mediate the activation of 5-LO nuclear import are as yet unknown. Phosphorylation of a protein can modulate its import into the nucleus, presumably by altering its capacity to bind to importin α . Recently, Fitzpatrick and colleagues presented evidence that 5-LO could be directly phosphorylated and that all phosphorylated 5-LO was associated with a DNA-containing nuclear fraction²³. This suggests that direct phosphorylation might play a role in the nuclear import of 5-LO. Nuclear import may also be regulated through intermolecular interactions. Coactosin-like protein, a protein found to interact with 5-LO in a yeast two-hybrid screen³¹, is a homologue of the actin-binding protein coactosin. This protein could function to anchor 5-LO to the cytoskeleton and thus retain it in the cytoplasm. In this scenario,

phosphorylation of 5-LO might serve to release it from the cytoskeleton and allow its subsequent import. Alternatively, nuclear import of 5-LO could be constitutive and 5-LO subcellular distribution regulated at the level of nuclear export. 5-LO contains several regions that resemble nuclear export sequences; the functional importance of each of these sequences has yet to be evaluated.

The Impact of Nuclear Import of 5-LO

Effect on LT secretion

The discovery that 5-LO can migrate into the nucleus in unstimulated cells immediately raised the question: Why? If the sole function of 5-LO is to make LTs for secretion, then why should 5-LO move from the cytoplasm into the nucleus? The most obvious answer is that nuclear import is necessary for LT synthesis. This possibility was supported by the finding that mutations that eliminated nuclear import of 5-LO also inhibited LT synthesis⁹. However, when nuclear import is induced in eosinophils, LT synthesis actually declines⁴. Thus, 5-LO import is not necessary for LT synthesis, at least in eosinophils.

A related purpose of nuclear import may be to alter 5-LO function and, in this way, modulate LT synthesis. This effect has been found. In neutrophils, import is induced by either adherence or recruitment into sites of inflammation. Blood neutrophils, which have cytoplasmic 5-LO, secrete abundant LTB₄. However, adherent neutrophils, which have intranuclear 5-LO, require a greater stimulus to activate LT synthesis but secrete 3 to 5 times as much LTB₄ as blood neutrophils⁵. Similarly, blood monocytes have cytoplasmic 5-LO and make low amounts of LTs. Differentiation of monocytes to macrophages can have two outcomes. If differentiation occurs in the peritoneum, then 5-LO distribution is not altered and there is little change in LT generation. On the other hand, if differentiation occurs in the alveolus, then 5-LO accumulates in the nucleus and LT synthesis increases dramatically^{3, 30}. This suggests that factors in the alveolus can drive both nuclear import and an increase in LTB₄ production. Supporting this conclusion is the finding that the removal of macrophages from the alveolus into culture results in the loss of both the nuclear 5-LO and the increased LTB₄ synthetic capacity¹¹. While these findings suggest that nuclear localization of 5-LO is associated with an increase in secretable LT synthesis, this correlation is not always the case. As noted above, the nuclear import of

5-LO in eosinophils, following adherence, leads to a dramatic decrease in LTC₄ secretion following cell stimulation⁴. It is not clear whether this reversal in the impact of nuclear import is related to inherent differences between cell types or relates more to differences in the LTB₄ vs. LTC₄ synthetic pathways.

There are several possible ways that a change in the subcellular distribution of 5-LO could lead to a change in the amount of secreted LT. One relates to the subcellular distribution of other enzymes linked in the metabolism of arachidonic acid to each type of LT. For example, the positioning of LTC₄ synthase on perinuclear membranes²⁹ may place it close to 5-LO moving to membranes from the cytoplasm, but distant from 5-LO moving from the nucleoplasm. The nuclear import of 5-LO, in effect, may result in an uncoupling of the enzymes in the LTC₄ synthetic pathway. Alternatively, the microenvironments of the nucleus and cytoplasm may differ subtly, perhaps in pH or reducing capacity, producing significant changes in the biochemical characteristics of the 5-LO enzyme. Or, the availability or regulation of essential co-factors, like calcium and ATP, may differ between the two compartments. The regulation of calcium signaling within the nucleus appears to vary with cell type and stimulus, so that in some cases nuclear calcium levels change independently from cytosolic calcium levels and in other cases the changes in the two compartments are linked. As a result, the import of 5-LO into the nucleus may serve to buffer it from activation by calcium signaling that occurs in the cytoplasm. These possibilities are yet to be clarified.

Intracellular actions of LTs

An extremely attractive explanation for the subcellular redistribution of 5-LO is that its products have intracellular effects, close to the site of synthesis. Thus, LTs synthesized by cytosolic 5-LO are available to modulate cytosolic processes and LTs synthesized by nuclear 5-LO are available to modulate nuclear processes (Fig. 4). LTs have been reported to influence a variety of cellular processes, although the specific mechanisms of action have not been elucidated. Secreted LTs are known to initiate their effects on target cells by binding to specific LT receptors on the cell surface^{24, 38}. In addition, LTB₄ has been shown to bind to the intracellular protein PPAR α , a nuclear receptor, and modulate its activity¹³. These results demonstrate that LTs are capable of binding to proteins and influencing their activity. Thus, LTs could potentially affect other intracellular functions by binding to intracel-




Fig. 4. Schematic diagram of the compartmentalization of 5-LO action. The two regulated processes of nuclear import and export will place 5-LO in either the nucleoplasm or the cytoplasm. This difference in localization will result in membrane association of 5-LO, after cell stimulation, on distinct membranes of the nuclear envelope. The synthesized LTs may then be generated in distinct compartments, producing different effects on leukocyte function

lular proteins and acting as activators, cofactors or inhibitors. Cytosolic processes that may be directly regulated by LTs include phagocytosis and bacterial killing, the activity of cytosolic enzymes, and cytoskeletal rearrangement. Nucleoplasmic events that may be regulated by LTs include gene transcription, apoptosis and DNA replication and repair. The autocrine action of LTs is a new field of study that should bear interesting fruit in the near future.

In the search for subcellular actions of 5-LO products, initial interest may focus on the effects of LTB₄, if only because it is the best recognized product. However, the more immediate products of 5-LO action, 5-HPETE, 5-HETE and LTA₄, may also be important. It should be noted that the amounts of these mediators that may be necessary to alter intracellular functions may be very small relative to the amounts normally made for secretion. As a result, the level of 5-LO activity that is required may also be very low. This suggests that the roles of FLAP and membrane association may be reduced. It is even possible that the residual activity of 5-LO in the absence of calcium activation may be sufficient to produce enough lipid mediator for intracellular effects. In short, most of our assumptions regarding the regulation of 5-LO may not apply to the metabolism of arachidonic acid for intracellular signaling.

Direct effects of 5-LO

A surprising implication for nuclear import of 5-LO involves the enzyme itself. Early immunoelectron microscopy analysis found 5-LO to be particularly abundant in the euchromatin region of nuclei of alveo-

lar macrophages³⁷. The euchromatin is the site of active DNA transcription. This suggests that the 5-LO protein may associate with active DNA and directly affect transcription. A portion of the 5-LO protein in the nuclear pellet from rat basophilic leukemia cells was found to be resistant to extraction with high salt concentrations, consistent with a tight association with chromatin⁷. LEPLEY and FITZPATRICK²² supported this possibility with evidence that tyrosine phosphorylated 5-LO was associated with DNA from activated HL-60 cells. The significance of the association of 5-LO with DNA remains to be elucidated.

Alternatively, 5-LO may interact with other proteins. LEPLEY and FITZPATRICK²⁰ demonstrated that 5-LO contains a functional Src homology 3-binding motif, which is a domain recognized by adapter proteins that mediate protein-protein linkages. Direct association of 5-LO with other proteins has also been identified by yeast two-hybrid studies³¹. These studies indicate that a variety of direct interactions between 5-LO and other proteins can be found, but the functional significance of each interaction has yet to be determined. It seems likely that changes in the nuclear import of 5-LO will affect these interactions, or, alternatively, these interactions may affect changes in the subcellular distribution of 5-LO.

Conclusion

The recent finding that 5-LO can move into the nucleoplasm of resting myeloid cells has potentially far-reaching consequences for the role of LTs in immunity. The simple possibility that nuclear import may serve to modulate the level of secreted LT has obvious significance: because nuclear import is regulated, dysfunction in that regulation becomes a tenable basis for diseases featuring aberrant LT generation, such as asthma. At a more complex level, the subcellular redistribution of 5-LO may impact on autocrine actions of 5-LO products. Finally, evidence that 5-LO directly interacts with DNA and other proteins indicates that the 5-LO protein may have additional roles, beyond its AA-processing function, in regulating myeloid cells.

Acknowledgment. This work was supported by the National Institute of Allergy and Infectious Diseases (National Institutes of Health), grant AI043574.

References

1. ABRAMOVITZ M., WONG E., COX M., RICHARDSON C., LI C. and VICKERS P. (1993): 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. *Eur. J. Biochem.*, **215**, 105–111.
2. BAILIE M., STANDIFORD T., LAICHALK L., COFFEY M., STRIETER R. and PETERS-GOLDEN M. (1996): Leukotriene-deficient mice manifest enhanced lethality from *Klebsiella pneumoniae* in association with decreased alveolar macrophage phagocytic and bactericidal activities. *J. Immunol.*, **157**, 5221–5224.
3. BALTER M., TOEWS G. and PETERS-GOLDEN M. (1989): Different patterns of arachidonate metabolism in autologous human blood monocytes and alveolar macrophages. *J. Immunol.*, **142**, 602–608.
4. BROCK T., ANDERSON J., FRIES F., PETERS-GOLDEN M. and SPORN P. (1999): Decreased leukotriene C₄ synthesis accompanies nuclear import of 5-lipoxygenase in human blood eosinophils. *J. Immunol.*, **162**, 1669–1676.
5. BROCK T., MCNISH R., BAILIE M. and PETERS-GOLDEN M. (1997): Rapid import of cytosolic 5-lipoxygenase into the nucleus of neutrophils after *in vivo* recruitment and *in vitro* adherence. *J. Biol. Chem.*, **272**, 8276–8280.
6. BROCK T., MCNISH R. and PETERS-GOLDEN M. (1998): Capacity for repeatable leukotriene generation following transient stimulation of mast cells and macrophages. *Biochem. J.* **329**, 519–525.
7. BROCK T. G., PAINE R. and PETERS-GOLDEN M. (1994): Localization of 5-lipoxygenase to the nucleus of unstimulated rat basophilic leukemia cells. *J. Biol. Chem.*, **269**, 22059–22066.
8. CHAKRABORTI T., MANDAL M., DAS S. and CHAKRABORTI S. (1999): Age-dependent change in arachidonic acid metabolic capacity in rat alveolar macrophages. *Biochem. Mol. Biol. Int.*, **47**, 501–507.
9. CHEN X.-S., ZHANG Y.-Y. and FUNK C. (1998): Determinants of 5-lipoxygenase nuclear localization using green fluorescent protein-5-lipoxygenase fusion proteins. *J. Biol. Chem.*, **273**, 31237–31244.
10. COFFEY M., PHARE S., KAZANJIAN P. and PETERS-GOLDEN M. (1996): 5-Lipoxygenase metabolism in alveolar macrophages from subjects infected with the human immunodeficiency virus. *J. Immunol.*, **157**, 393–399.
11. COVIN R., BROCK T., BAILIE M. and PETERS-GOLDEN M. (1998): Altered expression and localization of 5-lipoxygenase accompany macrophage differentiation in the lung. *Am. J. Physiol.*, **275**, L303–L310.
12. COWBURN A., HOLGATE S. and SAMPSON A. (1999): IL-5 increases expression of 5-lipoxygenase-activating protein and translocates 5-lipoxygenase to the nucleus in human blood eosinophils. *J. Immunol.*, **163**, 456–465.
13. DEVCHAND P., KELLER H., PETERS J., VAZQUEZ M., GONZALEZ F. and WAHLI W. (1996): The PPAR α -leukotriene B₄ pathway to inflammation control. *Nature*, **384**, 39–43.
14. DIXON R. A. F., DIEHL R. E., OPAS E., RANDS E., VICKERS P. J., EVANS J. F., GILLARD J. W. and MILLER D. K. (1990): Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. *Nature*, **343**, 282–284.
15. DRAZEN J. M., LILLY C. M., SPERLING R., RUBIN P. and ISRAEL E. (1994): Role of cysteinyl leukotrienes in spontaneous asthmatic responses. *Adv. Prostaglandin Thromboxane Leukot. Res.*, **22**, 251–262.
16. GORLICH D. (1997): Nuclear protein import. *Curr. Opin. Cell Biol.*, **9**, 412–419.
17. GORLICH D. and KUTAY U. (1999): Transport between the cell nucleus and the cytoplasm. *Annu. Rev. Cell Dev. Biol.*, **15**, 607–660.
18. HEALY A., PETERS-GOLDEN M., YAO J. and BROCK T. (1999):

- Identification of a bipartite nuclear localization sequence necessary for nuclear import of 5-lipoxygenase. *J. Biol. Chem.*, **274**, 29812–29818.
19. HILL E., MACLOUF J., MURPHY R. and HENSON P. (1992): Reversible membrane association of neutrophil 5-lipoxygenase is accompanied by retention of activity and a change in substrate specificity. *J. Biol. Chem.*, **267**, 22048–22053.
 20. LEPLY R. A. and FITZPATRICK F. (1994): 5-lipoxygenase contains a functional Src homology 3-binding motif that interacts with the Src homology 3 domain of Grb2 and cytoskeletal proteins. *J. Biol. Chem.*, **269**, 24163–24168.
 21. LEPLY R. A. and FITZPATRICK F. (1994): Irreversible inactivation of 5-lipoxygenase by leukotriene A₄. Characterization of product inactivation with purified enzyme and intact leukocytes. *J. Biol. Chem.*, **269**, 2627–2631.
 22. LEPLY R. and FITZPATRICK F. (1996): Inhibition of mitogen-activated protein kinase kinase blocks activation and redistribution of 5-lipoxygenase in HL-60 cells. *Arch. Biochem. Biophys.*, **331**, 141–144.
 23. LEPLY R., MUSKARDIN D. and FITZPATRICK F. (1996): Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. *J. Biol. Chem.*, **271**, 6179–6184.
 24. LYNCH K. R., O'NEIL G. P., LIU Q., IM D. S., SAWYER N., METTERS K. M., COULOMBE N., ABRAMOVITZ M., FIGUEROA D. J., ZENG Z., CONNOLLY B. M., BAI C., AUSTIN C. P., CHATEAUNEUF A., STOCO R., GRIEG G. M., KARGMAN S., HOOKS S. B., HOSFIELD E., WILLIAMS D. L. JR., FORD-HUTCHINSON A. W., CASKEY C. T. and EVANS J. F. (1999): Characterization of the human cysteinyl leukotriene CysLT₁ receptor. *Nature*, **399**, 789–793.
 25. MALAVIYA R., MALAVIYA R. and JAKSCHIK B. A. (1993): Reversible translocation of 5-lipoxygenase in mast cells upon IgE/antigen stimulation. *J. Biol. Chem.*, **268**, 4939–4944.
 26. McMILLAN R., MASTER D., VICKERS V., DICKEN M. and JACOBS V. (1989): Metabolism of unsaturated fatty acids by RBL-1 5-lipoxygenase: influence of substrate solubility and product inactivation. *Biochim. Biophys. Acta*, **1005**, 170–176.
 27. NAKIELNY S. and DREYFUSS G. (1999): Transport of proteins and RNAs in and out of the nucleus. *Cell Press*, **99**, 677–690.
 28. NEEDLEMAN P., TURK J., JAKSCHIK B. A., MORRISON A. R. and LEFKOWITH J. B. (1986): Arachidonic acid metabolism. *Annu. Rev. Biochem.*, **55**, 69–102.
 29. PENROSE J., SPECTOR J., LAM B., FRIEND D., XU K., JACK R. and AUSTEN K. (1995): Purification of human lung LTC₄ synthase and preparation of a polyclonal antibody. *Am. J. Respir. Crit. Care Med.*, **152**, 283–289.
 30. PETERS-GOLDEN M., MCNISH R. W., HYZY R., SHELLY C. and TOEWS G. B. (1990): Alterations in the pattern of arachidonate metabolism accompany rat macrophage differentiation in the lung. *J. Immunol.*, **144**, 263–270.
 31. PROVOST P., SAMUELSSON B. and RADMARK O. (1999): Interaction of 5-lipoxygenase with cellular proteins. *Proc. Natl. Acad. Sci., USA*, **96**, 1881–1885.
 32. RACHELEFSKY G. (1997): Childhood asthma and allergic rhinitis: the role of leukotrienes. *J. Pediatr.*, **131**, 348–355.
 33. ROUZER C. A. and KARGMAN S. (1988): Translocation of 5-lipoxygenase to the membrane in human leukocytes challenged with ionophore A23187. *J. Biol. Chem.*, **263**, 10980–10988.
 34. SAMUELSSON B. and FUNK C. D. (1989): Enzymes involved in the biosynthesis of leukotriene B₄. *J. Biol. Chem.*, **264**, 19469–19472.
 35. VIGGIANO D., ROMANO G., CANIGLIA M., SANTORO P., PALUMBO A. and CICIMARRA F. (1994): Impaired leukotriene B₄ release by neonatal polymorphonuclear leukocytes. *Pediatr. Res.*, **36**, 60–63.
 36. WILBORN J., BAILIE M., COFFEY M., BURDICK M., STRIETER R. and PETERS-GOLDEN M. (1996): Constitutive activation of 5-lipoxygenase in the lungs of patients with idiopathic pulmonary fibrosis. *J. Clin. Invest.*, **97**, 1827–1836.
 37. WOODS J., COFFEY M., BROCK T., SINGER I. and PETERS-GOLDEN M. (1995): 5-Lipoxygenase is located in the euchromatin of the nucleus in resting human alveolar macrophages and translocates to the nuclear envelope upon cell activation. *J. Clin. Invest.*, **95**, 2035–2040.
 38. YOKOMIZO T., IZUMI T., CHANG K., TAKUWA Y. and SHIMIZU T. (1997): A G-protein-coupled receptor for leukotriene B₄ that mediates chemotaxis. *Nature*, **387**, 620–624.

Received in February 2000

Accepted in February 2000